These custom reports analyze a pathway, disease, tumor type or competitive set, and can include a thorough analysis of clinical data, biomarkers, epidemiology, market size and competitor activity. All our work comes with actionable insights and strategic recommendations.
Once our clients understand the competitive landscape, and the market opportunity for their product we often generate a path to market strategy.
One of the ways our consultants keep abreast of current pharma/biotech industry news is through writing about science and clinical data.
Following the recent 2011 European Multidisciplinary Cancer Congress (EMCC 2011), the joint meeting of ESMO, ECCO and ESTRO, Sally Church wrote an in-depth analysis of the phase II data for T-DM1 (trastuzumab emtansine) in first line metastatic breast cancer. You can read more on Pharma Strategy Blog.
Meanwhile on Biotech Strategy Blog, Pieter Droppert interviewed Dr Chris Parker about the phase III, ALSYMPCA trial results for radium-223 (Alpharadin) in advanced prostate cancer.
This radiopharmaceutical provides new treatment options for a neglected group of men who are unable to take chemotherapy. You can read more on Biotech Strategy Blog, and also watch the video interview below: